Systematic review suggests omega-3 deficiency may be modifiable risk factor for mental disorders

A systematic review examined the role of omega-3 fatty acids—through dietary intake, deficiency, and supplementation—in the pathophysiology and treatment of various disorders. These included mental disorders (schizophrenia, affective and anxiety disorders, PTSD, eating disorders), neurodevelopmental disorders (ADHD, autism spectrum disorder), and neurodegenerative disorders (Alzheimer's disease). The review did not report specific population details, sample size, setting, comparator, or primary outcome measures.

The main finding is an increasing body of evidence suggesting that omega-3 deficiency and altered fatty acid profiles are modifiable risk factors and potential biomarkers for these disorders. The review explored potential therapeutic implications, noting that integration of omega-3 supplementation as an adjuvant to standard therapy offers potential for a low-risk intervention. It recommended clinical monitoring to avoid adverse effects and adjust dosage based on individual and disease-specific factors, though specific safety and tolerability data were not reported.

Key limitations include methodological variability and heterogeneous results across the studies reviewed. The evidence establishes association, not causation, and does not provide specific effect sizes or clinical trial data. The review's practice relevance is restrained: it summarizes existing evidence but does not establish definitive clinical protocols. The findings support the concept of omega-3 status as a factor in these disorders but highlight the need for more consistent research.